Treatment Review No. 14; November 1994
A drug research company called Hybridon has developed an antisense anti- HIV treatment called Gem91. Test-tube studies have shown Gem91 to be active against many isolates. Isolates are virus samples taken from different places. Unlike AZT, ddI and ddC, Gem91 appears to be active against HIV-infected macrophages. Macro-phages are types of cells known to be a major reservoir for HIV infection. Antisense drugs can't stop cells from becoming infected, but will hopefully stop the cells from making more virus. Neither the long-term safety nor how well the drug works has been proven.
Test-tube studies of Gem91 showed that it shut down replication of the virus for more than 80 days in HIV-infected human cells. In early trials the drug was tolerated with no side effects. Further studies are necessary to see if Gem91 can stop the virus's ability to replicate so the immune system can effectively act against infection.
A trial of Gem91 is enrolling in New York. This is an intensive Phase I trial requiring three weeks of hospitalization for IV therapy. Participants will be paid. For more information about this trial, call The Network at (800) 858-2111.
941101
ATR01402
Copyright © 1994 - AIDS Treatment Data Network. If you want to copy, reproduce or excerpt this information, please give us a call at (800) 734-7104. This helps up to keep track of where and how this information is being used. You can also Email us at network@atdn.org http://206.179.124.69/network/index.html